Alnylam Pharmaceuticals signed a license and research agreement with Scenic Biotech for RNAi therapeutics.
1 report, 1 independent
Updated Aug 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alnylam Pharmaceuticals signed a license and research agreement with Scenic Biotech for RNAi therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireScenic Enters License and Research Agreement with Alnylam Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license